Kansas City, KSNCT06538064Now EnrollingIRB Ready

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Clinical Trial in Kansas City, KS

Access cutting-edge chronic inflammatory demyelinating polyradiculoneuropathy (cidp) treatment through this clinical trial at a research site in Kansas City. Study-provided care at no cost to qualified participants.

Sponsored by Takeda

Quick Self-Assessment

See if you qualify for this Kansas City location

Preparing your pre-screening questions…

Expert Care in Kansas City

Access chronic inflammatory demyelinating polyradiculoneuropathy (cidp) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related chronic inflammatory demyelinating polyradiculoneuropathy (cidp) treatment provided free

Apply for This Kansas City Location

Check if you qualify for this chronic inflammatory demyelinating polyradiculoneuropathy (cidp) clinical trial in Kansas City, KS

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Kansas City

    Convenient for KS residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Kansas City site if eligible
  4. 4Begin participation

About This Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Study in Kansas City

The main aims of this study are to understand why adults with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) chose a certain treatment, why they changed to HyQvia from another therapy, how satisfied they are with HyQvia and their previous treatment, how their work productivity and activity is impacted and learn about their CIDP signs and symptoms. Other aims are to collect information on any medical problems or side effects during the treatment with HyQvia, learn how effective treatment of CIDP with HyQvia is and understand details on the use of HyQvia in standard clinical routine as well on the need for healthcare intervention (such as emergency room visits or hospital visits or stays). During the study, data will be collected from medical records already available, interviews with participants at study start and study completion and via questionnaires completed by participants. Participants will be treated as per the doctor's or the clinic's routine.

Sponsor: Takeda

Who Can Participate

Inclusion Criteria

Participants aged 18 years or older.
Investigator-confirmed documented diagnosis of CIDP of any type (e.g., typical, multifocal, focal, motor, sensory, or distal) according to the revised European Academy of Neurology and Peripheral Nerve Society (EAN/PNS) 2021 guidelines on the diagnosis and treatment of CIDP.
Participants must currently have a stable disease course (as per physician judgment) for at least 12 weeks.
Is considered a new user or current user of HyQvia-
New users (Cohort A) are participants on a CIDP treatment as of the date of enrollment, who intend to switch to HyQvia within 6 weeks after enrollment.
Current users (Cohort B) are participants on HyQvia as of the date of enrollment, who switched to HyQvia within the 6 weeks preceding the date of enrollment (the 6-week window may be extended depending on the recruitment progress).
Has provided written informed consent (for the main study).
Participant is willing to comply with the protocol requirement of non-standard of care (non-SOC) assessments (e.g., adjusted inflammatory neuropathy cause and treatment (INCAT) assessment).
Participants must be able to communicate fluently in their local language (if they participate in the optional qualitative participant interview \[sub-study\].

Exclusion Criteria

Had any HyQvia use, defined as
any record of HyQvia use prior to enrollment for new users of HyQvia (Cohort A), and
any record of HyQvia use more than 6 weeks preceding the enrollment date (the 6-week window may be extended depending on the recruitment progress) for current users of HyQvia (Cohort B).
Without any prior treatment for CIDP.
Pregnant or breastfeeding.
Participants with known hypersensitivity to any component of HyQvia.
Has participated in an interventional clinical study within 30 days prior to enrollment or was scheduled to participate in an interventional clinical study during this study.
Has had major surgery within 12 weeks prior to enrollment, or has surgery planned during the time the participant is expected to participate in the study. Note: Participants with planned surgical procedures to be conducted under local anesthesia may participate. Kyphoplasty or vertebroplasty are not considered major surgeries.
Received induction treatment for CIDP during the past 12 weeks.
Participant is identified by the investigator as being unable or unwilling to cooperate with the study procedures.
(Cohort A) only: Participants who do not initiate HyQvia treatment within 6 weeks after enrollment.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Kansas City?

Yes, this clinical trial (NCT06538064) has an active research site in Kansas City, KS that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Treatment Options in Kansas City, KS

If you're searching for chronic inflammatory demyelinating polyradiculoneuropathy (cidp) treatment options in Kansas City, KS, this clinical trial (NCT06538064) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Kansas City research site is actively enrolling participants for this clinical trial. You'll receive care from experienced chronic inflammatory demyelinating polyradiculoneuropathy (cidp) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all chronic inflammatory demyelinating polyradiculoneuropathy (cidp) clinical trials near you to find additional studies recruiting in your area.

More Multiple Myeloma Trials in Kansas City, KS

See all multiple myeloma clinical trials recruiting in Kansas City — not just this study.

Browse Multiple Myeloma Trials in Kansas City →

Browse More Trials by Condition

Multiple Myeloma TrialsFollicular Lymphoma TrialsAlzheimers Disease TrialsNeuropathy TrialsRheumatoid Arthritis TrialsAtopic Dermatitis TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Kansas City?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Kansas City, KS